Sector News

St. Jude Medical Appoints David Dvorak to Its Board of Directors

August 6, 2015
Life sciences
(BUSINESS WIRE) – St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the appointment of David C. Dvorak — President and Chief Executive Officer of Zimmer Biomet — to its Board of Directors, effective August 4, 2015.
 
“We are very pleased to have David Dvorak join the St. Jude Medical Board of Directors”
 
Mr. Dvorak has been President and Chief Executive Officer and a member of the Board of Directors of Zimmer Holdings Inc., a worldwide leader in musculoskeletal health care, for eight years. Mr. Dvorak joined Zimmer Holdings Inc. in December 2001 — shortly following the company’s spin-off from Bristol-Myers Squibb — and has served in many executive roles including Group President of Global Businesses, Chief Legal Officer, Executive Vice President of Corporate Services, Chief Counsel and Secretary, Chief Compliance Officer, and Senior Vice President of Corporate Affairs and General Counsel. He currently serves as a member of the Board of Directors of the Advanced Medical Technology Association (AdvaMed), and previously served as Chairman of the Board of AdvaMed.
 
“We are very pleased to have David Dvorak join the St. Jude Medical Board of Directors,” said St. Jude Medical Chairman, President and Chief Executive Officer Daniel J. Starks. “David is a distinguished leader in the medical technology industry and will offer a broad strategic perspective to our business. We look forward to his future contributions as St. Jude Medical continues to deliver on its innovation-based growth strategy.”
 
Source: St. Jude Medical

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.